Board of Directors

Executive Directors

Christopher Pearce - Chief Executive

Christopher Pearce has built the Group since inception and has been responsible for the formulation and implementation of strategy, collaborative and licensing agreements, and intellectual property. Formerly a Director of Smith New Court Securities plc, he has considerable City experience in research, marketing and corporate finance and was co-founder and Executive Chairman of Fitness First plc.

James Malthouse - Finance Director

James Malthouse joined the Group in 1993 and is a Chartered Accountant with banking and corporate finance experience. He was Chairman and Finance Director of Unigroup plc and Finance Director of Harcourt Group plc.

Non-Executive Directors

R Steven Harris – Chairman ^(i) (ii)

Steve Harris is a Fellow of the Royal Pharmaceutical Society. Until June 1995 he was Director of Development and Licensing at Medeva plc. He has worked in the pharmaceutical industry for 44 years including with ICI, Merck Sharp & Dohme, Eli Lilly, Boots, Reckitt and Colman, and Gensia. He is a non-executive Director of Advanced Medical Solutions plc and Phynova plc and is non-executive Chairman of Cyprotex plc and Aquapharm Biodiscovery Ltd.

Professor William Dawson ^(i) (ii)

Professor William Dawson retired from Eli Lilly and Company in August 1996 after 27 years' service, 14 as Research Director in the UK and latterly as Director of Technology Acquisition, Europe. He is a Director of Bionet Limited, Pharmovation Limited, Novolytics Limited, Antitope Limited and is Chair of the Board of Governors of De Montfort University, a Fellow of the Royal Pharmaceutical Society and of the Royal Society of Chemistry.

Dr Alf Lindberg  ⁽ⁱⁱ⁾

Dr. Alf A. Lindberg retired from his position as Executive Vice President of Research & Development at Aventis Pasteur in 2001. Before that he held the same position at Wyeth Vaccines between 1992 and 1995. From 1982 to 1992 he was Professor of Clinical Bacteriology at the Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden. He is a consultant to the biotech and pharmaceutical industry and a non-executive Director of Lytix A/S in Norway and Catella Healthcare Investment, Eurocine Vaccines and IscoNova AB in Sweden.